GGGeorg Golderer

Georg Golderer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Georg Golderer has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Gabriele Werner-Felmayer

    Institute of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria

    2 shared publications
  • Katrin Watschinger

    Institute of Molecular Biochemistry, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria

    2 shared publications
  • Markus Andreas Keller

    Institute of Human Genetics, Medical University of Innsbruck Innsbruck Austria

    2 shared publications
  • Adrie D. Dane

    Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, 1105, AZ, the Netherlands; Bioinformatics Laboratory, Department of Epidemiology & Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, 1105, AZ, the Netherlands

    1 shared publication
  • Dagmar Rudzki

    Department of Neurology, Medical University of Innsbruck, Innrain 66, 6020 Innsbruck, Austria

    1 shared publication
  • Eric J. M. Wever

    Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Alterations in ether lipid metabolism and the consequences for the mouse lipidome

    by Katharina Lackner, Sabrina Sailer, Jan-Bert van Klinken, Eric Wever, Mia L. Pras-Raves, Adrie D. Dane, Masanori Honsho, Yuichi Abe, Markus A. Keller, Georg Golderer, et al.


  • Open Access

    Repaglinide Silences the FOXO3/Lumican Axis and Represses the Associated Metastatic Potential of Neuronal Cancer Cells

    by Stefan Salcher, Gilles Spoden, Julia M. Huber, Georg Golderer, Herbert Lindner, Michael J. Ausserlechner, Ursula Kiechl-Kohlendorfer, Kathrin Geiger, Petra Obexer

    The transcription factor FOXO3 is associated with poor outcome in high-stage neuroblastoma (NB), as it facilitates chemoprotection and tumor angiogenesis. In other tumor entities, FOXO3 stimulates metastasis formation, one of the biggest challenges in the treatment of aggressive NB. However, the impact of FOXO3 on the metastatic potential of neuronal tumor cells remains largely unknown. In the present study, we uncover the small leucine-rich proteoglycan family member lumican (LUM) as a FOXO3-regulated gene that stimulates cellular migration in NB. By a drug-library screen we identified the small molecular weight compound repaglinide (RPG) as a putative FOXO3 inhibitor. Here, we verify that RPG binds to the FOXO3-DNA-binding-domain (DBD) and thereby silences the transcriptional activity of FOXO3. Consistent with the concept that the FOXO3/LUM axis enhances the migratory capacity of aggressive NB cells, we demonstrate that stable knockdown of LUM abrogates the FOXO3-mediated increase in cellular migration. Importantly, FOXO3 inhibition by RPG represses the binding of FOXO3 to the LUM promoter, inhibits FOXO3-mediated LUM RNA and protein expression, and efficiently abrogates FOXO3-triggered cellular “wound healing” as well as spheroid-based 3D-migration. Thus, silencing the FOXO3/LUM axis by the FDA-approved compound RPG represents a promising strategy for novel therapeutic interventions in NB and other FOXO3-dependent tumors.


  • Open Access

    Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis

    by Michael Auer, Harald Hegen, Dagmar Rudzki, Georg Golderer, Florian Deisenhammer

    Two-dimensional difference gel electrophoresis (2D-DIGE) has been used for identification of possible biomarkers in the cerebrospinal fluid (CSF) of multiple sclerosis (MS) patients. However, in different studies inconsistent results have been obtained. We wanted to analyze the diagnostic value of 2D-DIGE in early MS patients by comparing protein patterns between single and pooled samples of MS patients and controls. CSF samples of 20 MS patients and 10 control subjects were processed with 2D-DIGE. The so obtained protein patterns were analyzed with DeCyder 6.5 software, whereby we described variation of patterns presented in one gel as well as between different gels. Even when running single samples of patients of the same group in one gel, variation of protein patterns was high. The number of identified spots with different protein level varied between 4 and 30, depending on which sample batches were compared. We did not find a consistent pattern throughout all possible batch combinations. The inter-individual variation of protein expression as well as the susceptibility of 2D-DIGE for methodological variations makes use of 2D-DIGE as a diagnostic tool for MS and for detection of possible candidate biomarkers difficult, since detected proteins vary depending on which samples are compared.


  • Open Access

    Expression of full-length human alkylglycerol monooxygenase and fragments in Escherichia coli

    by Matthias Mayer, Markus A. Keller, Katrin Watschinger, Gabriele Werner-Felmayer, Ernst R. Werner, Georg Golderer

    Alkylglycerol monooxygenase (AGMO; EC 1.14.16.5) is the only enzyme known to cleave the O-alkyl ether bond of alkylglycerols in humans. It is an integral membrane protein with nine predicted transmembrane domains. We attempted to express and purify full-length and truncated forms of AGMO in Escherichia coli . Full-length AGMO could not be expressed in three different E. coli expression strains, three different expression vectors and several induction systems. We succeeded, however, in expression of three N-terminally strep-tagged truncated forms, named active sites 1, 2 and 3, with 205, 134 and 61 amino acids, respectively. Active site 1 fragment, containing two predicted transmembrane regions, a membrane associated region and all known amino acid residues important for catalytic activity, was not fully soluble even in 8 M urea. Active site 2 containing only one predicted membrane associated domain required 8 M urea for solubilisation and eluted in gel filtration in 1 M urea as a trimer. Active site 3 with no hydrophobic domain eluted in gel filtration in 1 M urea as monomer and dimer. These results show that even truncated forms of AGMO are barely soluble when expressed in E. coli and show a high tendency for aggregation.


  • Open Access

    A first glimpse at the transcriptome of Physarum polycephalum

    by Gernot Glöckner, Georg Golderer, Gabriele Werner-Felmayer, Sonja Meyer, Wolfgang Marwan

    Physarum polycephalum, an acellular plasmodial species belongs to the amoebozoa, a major branch in eukaryote evolution. Its complex life cycle and rich cell biology is reflected in more than 2500 publications on various aspects of its biochemistry, developmental biology, cytoskeleton, and cell motility. It now can be genetically manipulated, opening up the possibility of targeted functional analysis in this organism.